Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells

References

• Backstrom JR, Sanders-Bush E. Generation of anti-peptide antibodies against serotonin 5-HT2A and 5-HT2C receptors. J Neurosci Methods 1997; 77: 109–117
   PubMed Web of Science ®Google Scholar
• Baldin V, Roman AM, Bosc-Bierne I, Amalric F, Bouche G. Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J 1990; 9: 1511–1517
   PubMed Web of Science ®Google Scholar
• Beitz JG, Davol P, Clark JW, Kato J, Medina M, Frackelton AR, Jr, Lappi DA, Baird A, Calabresi P. Antitumor activity of basic fibroblast growth factor–saporin mitotoxin in vitro and in vivo. Cancer Res 1992; 52: 227–230
   PubMed Web of Science ®Google Scholar
• Bohlen P, Stein S, Dairman W, Udenfriend S. Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys 1973; 155: 213–220
   PubMed Web of Science ®Google Scholar
• Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575–606
   PubMed Web of Science ®Google Scholar
• Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000; 60: 7163–7169
   PubMed Web of Science ®Google Scholar
• Danielsen T, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer 1998; 76: 836–841
   PubMed Web of Science ®Google Scholar
• Davies MM, Burke D, Carnochan P, Glover C, Kaur S, Allen-Mersh TG. Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake. Acta Oncol 2002; 41: 84–90
   PubMed Web of Science ®Google Scholar
• Davis JC, Venkataraman G, Shriver Z, Raj PA, Sasisekharan R. Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans. Biochem J 1999; 341: 613–620
   PubMed Web of Science ®Google Scholar
• Davol PA, Frackelton AR, Jr. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance. Prostate 1999; 40: 178–191
   PubMed Web of Science ®Google Scholar
• Dow JK, deVere White RW. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000; 55: 800–806
   PubMed Web of Science ®Google Scholar
• Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5: 1063–1071
   PubMed Web of Science ®Google Scholar
• Gross JL, Herblin WF, Dusak BA, Czerniak P, Diamond MD, Sun T, Eidsvoog K, Dexter DL, Yayon A. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993; 85: 121–131
   PubMed Web of Science ®Google Scholar
• Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14: 328–336
   PubMed Web of Science ®Google Scholar
• Halaban R, Ghosh S, Baird A. bFGF is the putative natural growth factor for human melanocytes. In Vitro Cell Dev Biol 1987; 23: 47–52
   PubMed Web of Science ®Google Scholar
• Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988; 3: 177–186
   PubMedGoogle Scholar
• Hashida M, Kawakami S, Yamashita F. Lipid carrier systems for targeted drug and gene delivery. Chem Pharm Bull 2005; 53: 871–880
   PubMed Web of Science ®Google Scholar
• Hoganson DK, Chandler LA, Fleurbaaij GA, Ying W, Black ME, Doukas J, Pierce GF, Baird A, Sosnowski BA. Targeted delivery of DNA encoding cytotoxic proteins through high-affinity fibroblast growth factor receptors. Hum Gene Ther 1998; 9: 2565–2575
   PubMed Web of Science ®Google Scholar
• Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 2001; 3: 105–112
   PubMed Web of Science ®Google Scholar
• Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, Hashida M. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim Biophys Acta 2000; 1524: 258–265
   PubMed Web of Science ®Google Scholar
• Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci 2001; 90: 105–113
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, Sasse J, Sullivan R, Smith JA. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci USA 1986; 83: 2448–2452
   PubMed Web of Science ®Google Scholar
• Klagsbrun M. The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res 1989; 1: 207–235
   PubMedGoogle Scholar
• Kleeff J, Fukahi K, Lopez ME, Friess H, Buchler MW, Sosnowski BA, Korc M. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 2002; 9: 522–532
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709–724
   PubMed Web of Science ®Google Scholar
• Lappi DA. Tumor targeting through fibroblast growth factor receptors. Semin Cancer Biol 1995; 6: 279–288
   PubMed Web of Science ®Google Scholar
• Managit C, Kawakami S, Yamashita F, Hashida M. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci 2005a; 94: 2266–2275
   PubMed Web of Science ®Google Scholar
• Managit C, Kawakami S, Yamashita F, Hashida M. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm 2005b; 301: 255–261
   PubMed Web of Science ®Google Scholar
• Maruyama K. PEG-immunoliposome. Biosci Rep 2002; 22: 251–266
   PubMed Web of Science ®Google Scholar
• Monsigny M, Roche AC, Midoux P. Uptake of neoglycoproteins via membrane lectin(s) of L1210 cells evidenced by quantitative flow cytofluorometry and drug targeting. Biol Cell 1984; 51: 187–196
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Olsnes S, Klingenberg O, Wiedlocha A. Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev 2003; 83: 163–182
   PubMed Web of Science ®Google Scholar
• Opanasopit P, Higuchi Y, Kawakami S, Yamashita F, Nishikawa M, Hashida M. Involvement of serum mannan binding proteins and mannose reseptors in uptake of mannosylated liposomes by macrophages. Biochim Biophys Acta 2001; 1511: 134–145
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, deLapeyriere O. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995; 61: 170–176
   PubMed Web of Science ®Google Scholar
• Qin M, Escuadro B, Sharma S, Batra RK. Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells. Am J Respir Cell Mol Biol 2005; 32: 211–217
   PubMed Web of Science ®Google Scholar
• Rusnati M, Urbinati C, Tanghetti E, Dell'Era P, Lortat-Jacob H, Presta M. Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proc Natl Acad Sci USA 2002; 99: 4367–4372
   PubMed Web of Science ®Google Scholar
• Safran M, Eisenstein M, Aviezer D, Yayon A. Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2. Biochem J 2000; 345: 107–113
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003; 42: 439–462
   PubMed Web of Science ®Google Scholar
• Schubert F, Zettl H, Hafner W, Krauss G, Krausch G. Comparative thermodynamic analysis of DNA–protein interactions using surface plasmon resonance and fluorescence correlation spectroscopy. Biochemistry 2003; 42: 10288–10294
   PubMed Web of Science ®Google Scholar
• Sosnowski BA, Gonzalez AM, Chandler LA, Buechler YJ, Pierce GF, Baird A. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J Biol Chem 1996; 271: 33647–33653
   PubMed Web of Science ®Google Scholar
• Soulet F, Bailly K, Roga S, Lavigne AC, Amalric F, Bouche G. Exogenously added fibroblast growth factor 2 (FGF-2) to NIH3T3 cells interacts with nuclear ribosomal S6 kinase 2 (RSK2) in a cell cycle-dependent manner. J Biol Chem 2005; 280: 25604–25610
   PubMed Web of Science ®Google Scholar
• Stenlund P, Babcock GJ, Sodroski J, Myszka DG. Capture and reconstitution of G protein-coupled receptors on a biosensor surface. Anal Biochem 2003; 316: 243–250
   PubMed Web of Science ®Google Scholar
• Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers. Eur J Cancer 1996; 32: 1504–1509
   Web of Science ®Google Scholar
• Venkataraman G, Sasisekharan V, Herr AB, Ornitz DM, Waksman G, Cooney CL, Langer R, Sasisekharan R. Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA 1996; 93: 845–850
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 1997; 33: 691–693
   PubMed Web of Science ®Google Scholar
• Wegner GJ, Lee HJ, Marriott G, Corn RM. Fabrication of histidine-tagged fusion protein arrays for surface plasmon resonance imaging studies of protein–protein and protein–DNA interactions. Anal Chem 2003; 75: 4740–4746
   PubMed Web of Science ®Google Scholar
• Wu SJ, Chaiken I. Biosensor analysis of receptor-ligand interactions. Methods Mol Biol 2004; 249: 93–110
   PubMedGoogle Scholar
• Yayon A, Aviezer D, Safran M, Gross JL, Heldman Y, Cabilly S, Givol D, Katchalski-Katzir E. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc Natl Acad Sci USA 1993; 90: 10643–10647
   PubMed Web of Science ®Google Scholar
• Ying W, Martineau D, Beitz J, Lappi DA, Baird A. Anti-B16-F10 melanoma activity of a basic fibroblast growth factor–saporin mitotoxin. Cancer 1994; 74: 848–853
   PubMed Web of Science ®Google Scholar